These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 23549873)

  • 1. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer.
    Yu KD; Zhu R; Zhan M; Rodriguez AA; Yang W; Wong S; Makris A; Lehmann BD; Chen X; Mayer I; Pietenpol JA; Shao ZM; Symmans WF; Chang JC
    Clin Cancer Res; 2013 May; 19(10):2723-33. PubMed ID: 23549873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
    Hancock BA; Chen YH; Solzak JP; Ahmad MN; Wedge DC; Brinza D; Scafe C; Veitch J; Gottimukkala R; Short W; Atale RV; Ivan M; Badve SS; Schneider BP; Lu X; Miller KD; Radovich M
    Breast Cancer Res; 2019 Aug; 21(1):87. PubMed ID: 31383035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A gene signature predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients.
    Zheng T; Pang Z; Zhao Z
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 30988073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer.
    Liu NQ; Stingl C; Look MP; Smid M; Braakman RB; De Marchi T; Sieuwerts AM; Span PN; Sweep FC; Linderholm BK; Mangia A; Paradiso A; Dirix LY; Van Laere SJ; Luider TM; Martens JW; Foekens JA; Umar A
    J Natl Cancer Inst; 2014 Feb; 106(2):djt376. PubMed ID: 24399849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
    Liu XY; Jiang W; Ma D; Ge LP; Yang YS; Gou ZC; Xu XE; Shao ZM; Jiang YZ
    Theranostics; 2020; 10(24):10940-10956. PubMed ID: 33042263
    [No Abstract]   [Full Text] [Related]  

  • 7. Breast Cancer Plasticity after Chemotherapy Highlights the Need for Re-Evaluation of Subtyping in Residual Cancer and Metastatic Tissues.
    Padzińska-Pruszyńska IB; Akbar MW; Isbilen M; Górka E; Kucukkaraduman B; Canlı SD; Dedeoğlu E; Azizolli S; Cela I; Akcay AG; Hakanoglu H; Bodnar L; Cierniak S; Kozielec Z; Pruszyński JJ; Bittel M; Gure AO; Król M; Taciak B
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk stratification of triple-negative breast cancer with core gene signatures associated with chemoresponse and prognosis.
    Kim EK; Park AK; Ko E; Park WY; Lee KM; Noh DY; Han W
    Breast Cancer Res Treat; 2019 Nov; 178(1):185-197. PubMed ID: 31342312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy.
    Jongen L; Floris G; Wildiers H; Claessens F; Richard F; Laenen A; Desmedt C; Ardui J; Punie K; Smeets A; Berteloot P; Vergote I; Neven P
    Breast Cancer Res Treat; 2019 Aug; 176(3):699-708. PubMed ID: 31106385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
    Zhang J; Yao L; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Int J Cancer; 2021 Feb; 148(4):941-949. PubMed ID: 32720318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
    Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L
    Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response.
    Mohammed AA; Elsayed FM; Algazar M; Rashed HE; Anter AH
    Asian Pac J Cancer Prev; 2020 Feb; 21(2):563-568. PubMed ID: 32102539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Omar M; Nuzzo PV; Ravera F; Bleve S; Fanelli GN; Zanettini C; Valencia I; Marchionni L
    J Transl Med; 2023 Nov; 21(1):811. PubMed ID: 37964363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.
    Bouchalova K; Svoboda M; Kharaishvili G; Vrbkova J; Bouchal J; Trojanec R; Koudelakova V; Radova L; Cwiertka K; Hajduch M; Kolar Z
    Tumour Biol; 2015 Jun; 36(6):4243-52. PubMed ID: 25616695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
    Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
    PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer.
    Hall C; Karhade M; Laubacher B; Anderson A; Kuerer H; DeSynder S; Lucci A
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S552-8. PubMed ID: 25968619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
    Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L
    BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the androgen receptor in triple-negative breast cancer.
    Rampurwala M; Wisinski KB; O'Regan R
    Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer.
    Criscitiello C; Bayar MA; Curigliano G; Symmans FW; Desmedt C; Bonnefoi H; Sinn B; Pruneri G; Vicier C; Pierga JY; Denkert C; Loibl S; Sotiriou C; Michiels S; André F
    Ann Oncol; 2018 Jan; 29(1):162-169. PubMed ID: 29077781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.